What are the current updates on chronic spontaneous urticaria, including its types, clinical variants, diagnostic approach, investigations, and treatment options?

Chronic Spontaneous Urticaria: Comprehensive Update

Definition and Clinical Presentation

Chronic spontaneous urticaria (CSU) is defined by recurrent wheals, angioedema, or both, occurring spontaneously for more than 6 weeks without identifiable external triggers. The condition affects approximately 1% of the global population, with peak incidence in females aged 30-50 years 1. Individual wheals typically last 2-24 hours (unlike physical urticaria where wheals resolve within 1 hour, except delayed pressure urticaria) 2.

Types and Clinical Variants

Pathogenic Endotypes

CSU is now understood through distinct immunologic mechanisms [@1-6@]:

• Type I Autoallergic CSU: Mediated by IgE autoantibodies against self-antigens causing FcεRI crosslinking
• Type IIb Autoimmune CSU: Mediated by mast cell-activating IgG or IgM autoantibodies against IgE or FcεRI
• Mixed/Overlap: Recent evidence shows many patients have coexistent IgE and IgG autoantibodies, blurring endotype boundaries 3
• Idiopathic: Patients not meeting criteria for either autoimmune subtype

Over 50% of CSU patients have identifiable autoimmune endotypes 1, with Type IIb autoimmune CSU characterized by low/very low total IgE levels and elevated IgG-anti-thyroid peroxidase (anti-TPO) antibodies [@4-6@].

Associated Comorbidities

• Chronic inducible urticaria: >10%
• Autoimmune thyroiditis: ~20%
• Metabolic syndrome: 6-20%
• Anxiety: 10-31%
• Depression: 7-29% 1

Diagnostic Approach: The 7 Cs Framework

The 2022 international guideline emphasizes a structured diagnostic workup with seven specific aims [@5-6@]:

1. Confirm diagnosis and exclude differential diagnoses (especially urticarial vasculitis if wheals last >24 hours)
2. Causes: Look for underlying autoimmune mechanisms
3. Cofactors: Identify triggers and aggravating factors
4. Comorbidities: Screen for associated conditions
5. Consequences: Assess impact on sleep, mental health, sexual function, social performance
6. Components: Evaluate predictors of disease course and treatment response
7. Course: Monitor disease activity, impact, and control

Essential Clinical Assessment

• Thorough history focusing on:

  • Duration and frequency of wheals
  • Presence of angioedema
  • Diurnal variation
  • Potential triggers (NSAIDs, infections, stress)
  • Impact on quality of life

• Physical examination including review of patient photo documentation of wheals/angioedema 4

• Patient-Reported Outcome Measures (PROMs):

  • Urticaria Control Test (UCT): Score ≤15 indicates inadequate control
  • Dermatology Life Quality Index (DLQI): ~40% of patients score >10, indicating very large/extremely large negative impact 1

Investigations

Basic Laboratory Tests (Required for All Patients)

The 2022 guideline mandates these baseline investigations [@3-6@]:

• Complete blood count with differential
• C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)
• Total IgE level (NEW in 2022 guideline)
• IgG-anti-thyroid peroxidase (anti-TPO) (NEW in 2022 guideline)

Key diagnostic insight: A high ratio of IgG-anti-TPO to total IgE is currently the best surrogate marker for Type IIb autoimmune CSU [@5-6@]. Patients with autoimmune CSU typically have low/very low total IgE and elevated anti-TPO 4.

Additional Testing for Antihistamine-Refractory Patients

For patients not responding to H1-antihistamines, consider [@1-2@]:

• Basophil activation test (under investigation for future guidelines)
• Autologous serum test (limited clinical relevance since omalizumab efficacy is independent of results)
• Testing for antibodies against IgE, FcεRI, or FcεRII
• These biomarkers may predict treatment outcomes with omalizumab or cyclosporine

Extended Testing (Only as Clinically Indicated)

Perform additional investigations only when history, physical examination, or basic tests suggest specific conditions—avoid routine extensive workups 4.

Treatment Algorithm: Streamlined 3-Step Approach

The 2022 international guideline revolutionized CSU management by simplifying the treatment algorithm from 4 steps to 3, with clear guidance on dosing, duration, and step-up/step-down protocols [@1-7@].

Step 1: Second-Generation H1-Antihistamines (First-Line)

Start with standard-dose second-generation H1-antihistamines (e.g., cetirizine 10mg, loratadine 10mg, fexofenadine 180mg daily) [@1-7@].

• Response rate: ~40% achieve partial/complete response at standard doses 1
• If inadequate control after 2-4 weeks (or earlier if symptoms intolerable): Increase dose up to 4-fold [@1-7@]
• Up-dosing response: 63% achieve disease control with 4-fold dosing 5
• UCT score ≤15 indicates need for dose escalation 4

Critical step-down protocol 4:

• Only step down after ≥3 consecutive months of complete control
• Reduce by no more than 1 tablet per month
• If breakthrough symptoms occur, return to last effective dose
• This approach assesses for spontaneous remission while minimizing treatment burden

Step 2: Omalizumab (Second-Line, Add-On Therapy)

If inadequate control persists after 2-4 weeks of up-dosed antihistamines (or earlier if intolerable), add omalizumab [@1-7@].

Dosing protocol [@4-6@]:

• Start: 300mg subcutaneously every 4 weeks
• If insufficient response: Up-dose by shortening interval and/or increasing dose
• Maximum dose: 600mg every 2 weeks
• Allow up to 6 months for response before declaring treatment failure
• Response rate: ~70% achieve complete disease control 5

Evidence basis: Robust double-blind placebo-controlled trials demonstrate efficacy 4. Higher doses show similar safety profile to standard dosing, with superior risk-benefit ratio compared to cyclosporine 4.

Predictors of poor response 1:

• Type IIb autoimmune CSU (IgG-mediated)
• At least 30% have insufficient response to omalizumab

Step 3: Cyclosporine (Third-Line, Add-On Therapy)

For patients failing omalizumab after up to 6 months (or earlier if intolerable), add cyclosporine [@1-7@].

Dosing and monitoring 4:

• Dose: Up to 5mg/kg body weight daily
• Response rate: 54-73% improve, particularly in Type IIb autoimmune CSU 1
• Monitoring: Check blood pressure and renal function (BUN, creatinine) every 6 weeks 4

Serious adverse effects 4:

• Hypertension
• Renal failure
• Seizures (in predisposed patients)
• Hirsutism
• Gingival hypertrophy

Clinical caveat: Cyclosporine is particularly effective in Type IIb autoimmune CSU patients who fail omalizumab, as this endotype responds poorly to anti-IgE therapy 1.

Newly Approved and Emerging Therapies (2025-2026)

Recently Approved Options

Dupilumab (IL-4Rα antagonist):

• FDA-approved in 2025 for antihistamine-refractory CSU 6
• Targets type 2 inflammation 7
• Provides alternative for omalizumab non-responders

Remibrutinib (oral BTK inhibitor):

• Approved in 2025 6
• Covalent BTK inhibitor
• Particularly promising for autoimmune phenotypes 7

Investigational Therapies Under Development

Barzolvolimab (anti-KIT monoclonal antibody):

• Depletes mast cells
• Largest phase 3 program in CSU history 6
• Targets mast cell activation and survival 7

Other emerging targets [@12-16@]:

• JAK inhibitors
• MRGPRX2 inhibitors
• Anti-TSLP antibodies
• IL-17 and IL-5 inhibitors
• Novel anti-IgE therapies (e.g., YH35324)
• Mast cell silencers

Treatment Selection Algorithm Based on Endotype

For optimal outcomes, tailor therapy to CSU endotype 3, 7:

1. Autoallergic (Type I) or unclear endotype:

   • Standard algorithm: Antihistamines → Omalizumab → Cyclosporine
   • High likelihood of omalizumab response

2. Autoimmune (Type IIb) CSU (low total IgE, high anti-TPO, high anti-TPO/IgE ratio):

   • Consider earlier escalation to cyclosporine if omalizumab fails
   • BTK inhibitors (remibrutinib) show particular promise
   • Dupilumab may be effective alternative

3. Refractory to all guideline-recommended therapies:

   • Consider emerging biologics (barzolvolimab, BTK inhibitors)
   • Enrollment in clinical trials

Off-Label and Adjunctive Options

Short-term systemic corticosteroids 2:

• Restrict to severe acute exacerbations or angioedema affecting airway
• Avoid prolonged use except for delayed pressure urticaria or urticarial vasculitis

Leukotriene receptor antagonists 5:

• May be added as adjunctive therapy
• Limited evidence but low risk

Combination strategies 2:

• H2-antihistamines with H1-antihistamines
• Sedating antihistamines at night for sleep disturbance

Common Pitfalls and How to Avoid Them

1. Premature extensive investigation: Avoid routine allergy testing, autoimmune panels beyond anti-TPO, or extensive imaging. Stick to basic tests unless clinically indicated 4.

2. Inadequate antihistamine trial: Must attempt 4-fold dosing for 2-4 weeks before declaring failure [@1-7@].

3. Premature omalizumab discontinuation: Allow full 6 months for response before switching to cyclosporine 4.

4. Aggressive step-down: Patients frequently relapse if stepped down too quickly. Follow the 3-month rule and 1-tablet-per-month reduction 4.

5. Missing Type IIb autoimmune CSU: Check total IgE and anti-TPO to identify patients likely to fail omalizumab who may benefit from earlier cyclosporine or BTK inhibitors [@4-6@].

6. Confusing CSU with urticarial vasculitis: If wheals last >24 hours, perform skin biopsy 2.

Quality of Life Considerations

CSU profoundly impacts quality of life, with 40% of patients reporting DLQI >10 1. The unpredictable nature of symptoms—sudden onset, variable severity, and inconsistent treatment response—substantially impairs daily functioning, sleep, mental health, and social/sexual performance 5. Achieving complete disease control (UCT >15) should be the therapeutic goal, not merely symptom reduction 4.

Future Directions

The next guideline update is planned for 2026, with anticipated inclusion of 4:

• Basophil activation test for routine use
• Refined biomarkers for treatment selection
• Integration of newly approved therapies (dupilumab, remibrutinib, barzolvolimab)
• Personalized treatment algorithms based on endotype

The expanding therapeutic armamentarium enables mechanism-informed, individualized treatment strategies, shifting CSU management from empiric sequential therapy toward precision medicine 6, 5.